Ligand Pharmaceuticals stock slipped about 2% after earnings, which might surprise anyone focused on its premium P/E and royalty driven reputation. The headline from this quarter is earnings power. Adjusted diluted earnings per share landed at about US$2.37 on revenue of roughly US$64 million, with royalty revenue doing most of the work.

Coming into the print, shares were already up strongly over the past three months. Today’s pullback looks more like a valuation check rather than a verdict on the quarter, which showed the royalty aggregation model throwing off solid profit again.

Is Ligand Pharmaceuticals really trading at a discount when its P/E sits above peers, or is the DCF implying something the market is not pricing in yet? See how NasdaqGM:LGND screens on our valuation analysis for Ligand Pharmaceuticals

Q2 2026 Earnings Summary

• Revenue Q2 2026 vs. Q2 2025: US$63.7 million vs. US$47.6 million (up about 34%)
• Net Income Q2 2026 vs. Q2 2025: US$48.5 million vs. US$4.8 million (sharply higher profit)
• Basic EPS Q2 2026 vs. Q2 2025: US$2.42 vs. US$0.25 (very large increase)
• Products Launched TTM Q2 2026 vs. TTM Q2 2025: 1 vs. 1 (steady launch activity across the royalty portfolio)

Prefer clean visuals instead of another wall of earnings tables and footnotes? See Ligand Pharmaceuticals' full financial picture with a clear view of its valuation in our company report for Ligand Pharmaceuticals.

Ligand bull case: royalty engine and XOMA test

Bulls argue that Ligand Pharmaceuticals has built a compounding royalty engine, now scaled up by XOMA, that can convert revenue into high margin earnings and cash flow. Q2 goes some way to backing that up. Royalty revenue of US$48 million supplied most of the US$63.7 million top line and supported adjusted EPS of US$2.37 and GAAP EPS of US$2.22. That is consistent with management’s focus on lower operating overhead and leverage to partnered drug sales such as Filspari and Ohtuvayre. The guidance lift at the low end of adjusted EPS and reaffirmed royalty revenue range points to management confidence that the expanded portfolio can sustain this earnings profile. Expected operating cash flow above US$200 million for 2026 and planned deployment into additional royalties also align with the reinvestment story behind the bullish narrative.

Bear case: concentration, dilution risk and quality of earnings

The bear view centers on concentration in a handful of therapies, execution risk across a broad pipeline, acquisition integration and the quality of Ligand Pharmaceuticals earnings. Q2 offers a mixed scorecard. Royalty growth tied to products such as Filspari and Ohtuvayre supports the dependence concern. Kyprolis royalties fell 17%, which shows individual product pressure can matter even when the portfolio is larger. The XOMA deal reduces single asset risk by adding more than 120 programs. It also increases reliance on partners to advance over 100 early and mid stage projects. EPS remains framed on an adjusted basis, while management flags accounting complexity from financial royalty assets and tax attributes, so headline profit still needs careful interpretation. The new zero coupon convertible and share repurchases partly address dilution worries, but longer term capital deployment discipline remains a key watch point for bears.

Compare that earnings power story with what the street is signaling on the stock. See the consensus price target analysis for Ligand Pharmaceuticals to check how current analyst targets line up with Ligand Pharmaceuticals latest royalty driven results.

Stay Ahead With Simply Wall St

If the latest earnings and royalty story around Ligand Pharmaceuticals has your attention, register for free with Simply Wall St and add the stock to a Watchlist to track share price against fair value and watch how the thesis develops. After you decide to build a position, keep on top of what matters most using the Portfolio Command Center that cuts through the noise and flags key changes to your holdings. For a broader view, lean on the Community to see how other investors are thinking about Ligand Pharmaceuticals and similar stocks. By surfacing potential catalysts and risks early, Simply Wall St helps you act faster and stay ahead of the market.

Seeking Fresh Alternatives Beyond Ligand?

Markets move fast and the best breakout ideas rarely stay under the radar for long. Catch fresh momentum while it matters, before prices start flying and opportunities drop away. Act now.

• Spot resilient opportunities that keep compounding through different cycles by scanning a curated 78 resilient stocks with low risk scores chosen for staying power rather than short lived hype.
• Ride potential upside in future facing infrastructure plays by reviewing a hand picked set of 36 power grid technology and infrastructure stocks positioned to benefit if grid upgrades gain momentum.
• Target potential growth tied to smarter factories and logistics using a focused group of 36 robotics and automation stocks that put automation and efficiency at the center of their business models.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.